ECM
IMVT icon

ExodusPoint Capital Management’s Immunovant IMVT Stock Holding History

ExodusPoint Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-107,300
Closed -$1.13M – 2361
2021
Q2 		$1.13M Buy
+107,300
New +$1.5M 0.01% 944

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ExodusPoint Capital Management's IMVT Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its Immunovant (IMVT) stake by 83% in Q1 2026, selling an estimated $2.71M and leaving 21,941 shares worth $545K. The position accounts for ﹤0.01% of the portfolio, ranked #1172.

ExodusPoint Capital Management first reported a position in IMVT in Q4 2019 and has held it in 17 quarters since. The position peaked at $3.87M in Q2 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • ExodusPoint Capital Management held 21,941 shares of Immunovant worth $545K as of Q1 2026.
  • ExodusPoint Capital Management sold 104,680 Immunovant shares in Q1 2026, an estimated $2.71M.
  • Immunovant made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1172 holding.
  • ExodusPoint Capital Management first reported a position in Immunovant in Q4 2019 and has held it in 17 quarters since.
  • ExodusPoint Capital Management's Immunovant position peaked at $3.87M in Q2 2025.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.